Clinical Value of DWI-ADC Matching in the Short-term Prognosis of Wilson's Disease

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06196931

Enrollment

200

Registered

2024-01-09

Start date

2024-01-01

Completion date

2026-12-31

Last updated

2024-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatolenticular Degeneration; Wilson

Keywords

DWI-ADC matching, Wilson disease, clinical value, short-term prognosis

Brief summary

In earlier studies, it was found that patients of Wilson disease with new diagnosed who only has neurological symptoms often had DWI hyper-intensity in brain MRI, which was more common in putamen and midbrain, indicating that the disease was in the acute stage. However, many patients had ADC hyper-intensity or hypo-intensity at the same time, and the two different signals represented different disease processes from an imaging perspective. The former indicating T2 penetration effect, and the latter represents diffusion limitation, which indicating the presence of local inflammation, edema, etc. Whether the signal changes of these two different matching modes have guiding significance for the early de-copper treatment for WD, one is the core point of our study. We hope to exploring the predictive value about DWI-ACD signal matching for symptoms changes in the earlier time of de-copper treatment through this study.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

1. Patients had been previously diagnosed with WD who both had DWI hyper-intensity and ADC hyper-intensity or hypo-intensity at the same time； 2. Patients who accept de-copper treatment in hospitalization for 4 weeks or more.

Exclusion criteria

1. Patients who only with liver injury; 2. Severe complications; 3. Combined with other diseases.

Design outcomes

Primary

Measure	Time frame	Description
UWDRS scales	Before and 4 weeks after treatment	It is used to evaluate the changes of patients' nervous system symptoms
24h urine copper	Before and 4 weeks after treatment	used to evaluate the changes of patients' nervous system symptoms

Secondary

Measure	Time frame	Description
Semi-quantitative brain MRI score	Before de-copper treatment	It is used to evaluate the changes of patients' nervous system symptoms
ALT, AST and other liver function test	Before and 4 weeks after treatment	used to evaluate the changes of patients' nervous system symptoms

Countries

China

Outcome results